Omeros Corp.

Omeros Corp. is a clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Lead drug product Omidria (OMS302) for lens replacement surgery is under review for marketing approval by both FDA and the European Medicines Agency, with U.S. commercial launch planned for H2/14. Omeros' five other clinical programs are focused on schizophrenia; Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros' proprietary G protein-coupled receptor (GPCR) platform is making available many new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Expert Comments:

Prescient Investment Analysis, Seeking Alpha (4/16/15)
"There are many reasons to believe that Omeros Corp.'s Ophthalmic product Omidria can be successful in domestic markets. Safety, ease of access, reduced stress upon surgeons, and reimbursement for use combine to make questions involving when it will be widely used more pressing than uncertainties pertaining to if it is going to happen. . .under conservative assumptions, Omidria can potentially generate $600M domestic sales revenue five years from now. . .worth over $200M to the corporation. Omidria appears to be a lucrative project that will finance the development of Omeros's pipeline!"

Jason Kolbert, Maxim Group (4/14/15)
"Omeros Corp. announced this morning that the presiding European regulatory authority has approved the company's investigational product OMS-721 for compassionate use. . .[in] the treatment of thrombotic microangiopathies. . .the two patients in the compassionate use study suffer from atypical hemolytic uremic syndrome and were enrolled in the first cohort of the Phase 2 clinical trial. Based on improvements across markers of disease activity in that cohort, the investigator requested that the company continue to provide OMS-721 so that the patients could extend their treatments."

"Omeros Corp. is an exciting company, and the CEO, Dr. Gregory Demopulos, is brilliant. The company is now in the early stages of launching Omidria (phenylephrine + ketorolac), for maintaining pupil dilation during surgery and reducing post-operative pain. While we are excited for the prospects for this drug, we view this as a means for the company to fund one of the most exciting biotechnology pipelines in the industry. The pipeline includes a PDE10 drug targeting schizophrenia and Huntington's disease, an antibody that targets the MASP-2 protein and may show efficacy in complement activation pathway disorders such as atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP) and neovascular age-related macular degeneration (AMD)." read more >

Jason Kolbert, Maxim Group (4/2/15)
"Omeros Corp. announced the nationwide commercial availability of Omidria for intraocular administration during cataract surgery and other intraocular lens replacement procedures to prevent intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. . .the Centers for Medicare & Medicaid Services has set the reimbursement rate for Omidria under Medicare Part B at the product's wholesale acquisition cost of $465 plus 6% per single-use vial. This price is above our expectations and should represent upside to our forecast."

Jason Kolbert, Maxim Group (3/17/15)
"Omeros Corp. ended 2014 with $6.8M in cash. . .for Omidria, the company began a 'controlled launch' in February to test its marketing and distribution systems. The full launch is planned for April, when the American Society of Cataract and Refractive Surgery holds its annual meeting. . .in addition to the PharmacoSurgery platform, Omeros has a pipeline of other products with high potential."

Ram Selvaraju, MLV & Co (3/13/15)
"We remain confident that Omeros Corp. is close to officially launching Omidria and project sales revenue starting in Q2/15. The transitional pass-through Medicare reimbursement status for Omidria is favorable. . .we believe that the European Medicines Agency will approve Omidria for the same indication in the E.U. in mid-2015. . .we continue to project that Omeros could achieve cash-flow-positive status in late 2015, and reach sustainable profitability in 2018 driven by the revenue trajectory for Omidria. . .we project that development of OMS824 for Huntington's disease (HD) will continue in H1/15. . .clinical trials in HD patients by H2/15."

More Comments

Experts Commenting on This Company

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.